iBio, Inc.

NYSE American IBIO

iBio, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2024: USD -12.95 M

iBio, Inc. EBITDA is USD -12.95 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 49.97% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

iBio, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -25.88 M, a 29.35% change year over year.
iBio, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -36.63 M, a -38.50% change year over year.
iBio, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -26.45 M, a -78.85% change year over year.
iBio, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -14.79 M, a -7.35% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NYSE American: IBIO

iBio, Inc.

CEO	Dr. Martin B. Brenner D.V.M., Ph.D.
IPO Date	Aug. 19, 2008
Location	United States
Headquarters	8800 HSC Parkway
Employees	16
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

Key trends

Past 5 years